| Revenue growth | 18% YoY growth in Q1FY27. |
|---|---|
| Margins | Adjusted EBITDA margin improved to 13.6% from 12.8%. |
| Demand visibility | Strong CDMO demand; expanding customer base to 926. |
| Management confidence | High; citing 14 consecutive quarters of growth. |
Growth
Generic Formulations CDMO grew 29% YoY; Exports surged 79%. Trade Generics declined 32% due to codeine product discontinuation.
Outlook
Plant-6 commercialization on track for H1FY27. Capex of ₹73 Cr in FY26 focused on OSD capacity expansion.
Risks
Trade Generics vertical faced headwinds from product discontinuation; non-cash ESOP expenses impacted reported margins.
Last quarter's promises, checked
Delivered
- Plant 6 commercialization by H1 FY27 → On track (= BEAT)
- Maintain ROCE/ROE above 25% → Sustained above 25% (= BEAT)
- Revenue growth outperforming IPM volume → 18% vs 3.4% (= BEAT)
Partly delivered
- Injectables scaling → Catching up but with earlier timeline lag (= PARTIAL)
Missed
- Trade Generics growth → -32% decline due to codeine exit (= MISS)
Investor Presentation filed with NSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹1,102.55
- Market cap
- ₹2,314 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 34.8×Sector 50.4×
- Promoter holding
- 63.31%+1.41% QoQ
- FII holding
- 2.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Earnings Call Transcript: Key Takeaways
Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.
Windlas Biotech Q1 FY27 Results: Net Profit ₹17.7 Cr, Up 0.0% YoY
Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹17.7 Cr · +0.0% YoY
Windlas Biotech Earnings Call: Key Takeaways
Windlas Biotech reported record FY26 revenue of ₹904cr (up 19% YoY) and highest post-listing EPS of ₹31.60. Management emphasized scalability, capital efficiency (ROCE/ROE >25%), and diversification into injectables and exports.
Windlas Biotech Earnings Call: Key Takeaways
Windlas Biotech reported record annual revenue of ₹904 Cr in FY26, a 19% YoY growth, driven by its CDMO vertical. The company maintained a strong net liquidity position of ₹251 Cr with zero net debt.
Windlas Biotech Q4 FY26 Results: Net Profit ₹16 Cr, Down 1.8% YoY
Windlas Biotech Ltd reported revenue from operations of ₹238.5 Cr (+17.7% YoY) and net profit of ₹16 Cr (-1.8% YoY) for Q4 FY26.
- Key figure
- Net profit ₹16 Cr · -1.8% YoY